✨ Free AI Report
Alumis Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Alumis Inc.
Company Research

Alumis Inc.: Business Overview, Financials & Competitive Analysis

Alumis Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Solid clinical-stage biotech with differentiated immunology focus and positive analyst momentum, but dependent on successful Phase trials and future financing. Alumis demonstrates solid fundamentals with a focused clinical pipeline, strong recent market momentum (up 5.23% weekly as of early March 2026), and institutional support. However, the clinical-stage status and current.

What is Alumis Inc.'s industry? Alumis Inc. (alumis.com) operates in Biopharmaceutical - Immunology / Autoimmune Disorders. AskCyborg classifies Alumis Inc. under Biopharmaceutical - Immunology / Autoimmune Disorders in its company registry.

Alumis is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and immune-mediated diseases. The company's pipeline includes ESK-001, a TYK2 inhibitor for plaque psoriasis and system...

6/ 10Solid

Cyborg Score thesis

Solid clinical-stage biotech with differentiated immunology focus and positive analyst momentum, but dependent on successful...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Immunology / Autoimmune Disorders
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Alumis Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Alumis Inc.

AskCyborg analysts argue the bull and bear cases for Alumis Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Alumis Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Alumis Inc. Overview

Pro stress-test →

Alumis is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and immune-mediated diseases. The company's pipeline includes ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus, and A-005 for neuroinflammatory conditions, positioning it to address significant unmet medical needs in immunology.

Strategic Profile

Pro stress-test →

Alumis leverages allosteric tyrosine kinase inhibitor technology and IRF5 targeting to differentiate its approach in the competitive immunology space. The company has attracted investor confidence, evidenced by recent analyst coverage with buy ratings and price targets above current trading levels, though it remains unprofitable as a clinical-stage biotech.

Competitive Landscape

Pro stress-test →

Alumis competes in the immunology therapeutics space with other clinical-stage biotech companies developing TYK2 inhibitors and immune-targeted therapies. The company differentiates through allosteric TYK2 selectivity and CNS-penetrant compounds, competing against established players and well-funded early-stage peers in autoimmune disease treatment.

Industry Context

Alumis Inc. operates in Biopharmaceutical - Immunology / Autoimmune Disorders.

Key facts

Founded: 2021 · Headquarters: South San Francisco, California · Employees: 168 · Revenue: null · Market cap: $3.70B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Alumis Inc..

  • Stock momentum is strong with recent all-time highs and market cap expansion to ~$3.7B as of March 2026
  • Clinical pipeline focused on validated TYK2 pathway with applications across psoriasis, lupus, and CNS conditions
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Director Srinivas Akkaraju increased stake with significant share acquisition
  • January 2026Analyst coverage initiated with buy ratings from Stifel (target $44) and Chardan Capital Markets
  • +1 moreTrack every material event for Alumis Inc. as it happens. Explore monitoring →
Get alerted when Alumis Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

TYK2 InhibitorsCompeting TYK2 inhibitor approach for immune disorders→Immunology PipelineVarious companies targeting TYK2, JAK, and immune pathways→

Compare Alumis Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Alumis Inc. operates in Biopharmaceutical - Immunology / Autoimmune Disorders. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Immunology / Autoimmune Disorders research →
NEW · MCP server

Ask your AI assistant about Alumis Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Alumis Inc. and its top competitor on Cyborg Score”
“What did Alumis Inc. do this quarter?”
“Is Alumis Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Alumis Inc. do?+
Alumis is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and immune-mediated diseases. The company's pipeline includes ESK-001, a TYK2 inhibitor for plaque psoriasis and system...
What is Alumis Inc.'s Cyborg Score?+
Alumis Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Alumis Inc.'s main competitors?+
Named competitors include TYK2 Inhibitors, Immunology Pipeline. The full competitive landscape is in the AskCyborg report.
How can I get the full Alumis Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Alumis Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Alumis Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Immunology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5InflaRx N.V.